"test and treat" strategy for treating transforming hpv infection
AssigneeNorchip A/S
InventorsHanne Skomedal, Einar Morland, Geir Morland, Frank Karlsen
Life of this patent
Estimating the term…
Abstract
The invention is concerned with a “test and treat” method of screening and directly treating female subjects having transforming or abnormal human papillomavirus (HPV) infection.
Claims32
A test and treat method of detecting and treating transforming infection with human papillomavirus (HPV) in a human female subject, the method consisting of:
- testing a cervical sample from the subject for expression of E6/E7 mRNA transcripts from at least one cancer-associated (high risk) or carcinogenic HPV type;
- making a treatment decision in a female human subject based on the outcome of the test for expression of E6/E7 mRNA transcripts of said at least one cancer-associated (high-risk) or carcinogenic HPV type, whereby a subject whose cervical sample tests positive for expression of E6/E7 mRNA transcripts from at least one cancer-associated (high risk) or carcinogenic HPV type is selected for direct treatment;
- and
- treating said subject to reduce or eliminate transforming infection with human papillomavirus (HPV).
A test and treat method of screening a population of female human subjects, selecting and treating individuals identified as having transforming infection with human papillomavirus (HPV) based on the outcome of a test for expression of E6/E7 mRNA transcripts of human papillomavirus (HPV), the method consisting of:
- testing cervical samples from subjects in the population for expression of E6/E7 mRNA transcripts from at least one cancer-associated (high risk) or carcinogenic HPV type;
- making a treatment decision based on the outcome of the test for expression of E6/E7 mRNA transcripts from at least one cancer-associated or carcinogenic HPV type in cervical samples from said subjects, whereby a subject whose cervical sample tests positive for expression E6/E7 mRNA transcripts from at least one cancer-associated or carcinogenic HPV type is selected for direct treatment;
- and
- treating said subject to reduce or eliminate transforming infection with human papillomavirus (HPV).
A test and treat method of triaging female subjects having a previous diagnosis of ASC-US, low-grade cervical lesions (LSIL) or high-grade cervical lesions (HSIL) by cytology, selecting and treating individuals identified as having transforming infection with human papillomavirus (HPV) based on the outcome of a test for expression of E6/E7 mRNA transcripts of human papillomavirus (HPV), the method consisting of:
- testing a cervical sample from a subject having a previous diagnosis of ASC-US, low-grade cervical lesions (LSIL) or high-grade cervical lesions (HSIL) by cytology for expression of E6/E7 mRNA transcripts from at least one cancer-associated (high risk) or carcinogenic HPV type;
- making a treatment decision based on the outcome of the test for expression of E6/E7 mRNA transcripts from at least one cancer-associated (high risk) or carcinogenic HPV type in said cervical sample, whereby a subject whose cervical sample test positive for expression of E6/E7 mRNA transcripts from at least one cancer-associated or carcinogenic HPV type is selected for direct treatment;
- and
- treating said subject to reduce or eliminate transforming infection with human papillomavirus (HPV).
A test and treat method of triaging female subjects who previously tested positive for the presence of DNA from at least one cancer-associated (high risk) or carcinogenic HPV type, selecting and treating individuals identified as having transforming infection with human papillomavirus (HPV) based on the outcome of a test for expression of E6/E7 mRNA transcripts of human papillomavirus (HPV), the method consisting of:
- testing a cervical sample from a subject who previously tested positive for the presence of DNA from at least one cancer-associated (high risk) or carcinogenic HPV type for expression of E6/E7 mRNA transcripts from at least one cancer-associated (high risk) or carcinogenic HPV type;
- making a treatment decision based on the outcome of the test for expression of E6/E7 mRNA transcripts from at least one cancer-associated or carcinogenic HPV type in said cervical sample, whereby a subject whose cervical sample tests positive for expression E6/E7 mRNA transcripts from at least one cancer-associated or carcinogenic HPV type is selected for direct treatment;
- and
- treating said subject to reduce or eliminate transforming infection with human papillomavirus (HPV).
Dependencies are inferred from the claim text.